

## R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies (Celaid Therapeutics Inc.)



City	Year of Establishment	Founder
Bunkyo-ku, Tokyo	2020	Nobuyuki Arakawa

Partner VC	Latest round of Fundraising	Valuation
The University of Tokyo Edge Capital Partners (UTEC)	Series A extension	Non-Disclosure

Contact Information :

e-mail: [contact@celaidtx.com](mailto:contact@celaidtx.com)

Website : <https://celaidtx.com/en/>

### ○ Business Plan

Celaid will establish and validate systems for supplying clinical and commercial-grade HSC expansion methods and culture media to the biotechnology field enabling global biotech/pharmaceutical companies to address their technical challenges encountered in commercial manufacturing of cell and gene therapy products.

### ○ Research Outline

Through this R&D effort, clinical and commercial-grade HSC expansion methods and culture media will be established (R&D #1&2). In parallel, experiments on the application of HSC expansion technology to cell and gene therapy products will be conducted (R&D #3&4).

R&D #1. Establishment of clinical-grade culture media

R&D #2. Development of HSC expansion manufacturing process

R&D #3. Application to the manufacturing process of ex vivo gene therapy products

R&D #4. Application to the manufacturing process of cell therapy products

Business Area/Field	Research Period	Research Amount	International collaborative technology demonstration
Healthcare	STS 2024~2025FY	JPY 199 million	United States, Europe etc.

As of May,2024